Cambridge Healthtech Institute’s Inaugural

Bispecific Antibody Design and Applications

Maximizing I-O Therapeutic Potential with Novel Platforms

11-12 March, 2020

As a growing class of immunotherapies, bispecific antibodies continue to show significant and impressive therapeutic value. While the development of bispecific antibodies is an evolving field, many challenges are still waiting to be solved by experts in the field including target selection, better understanding of their mechanism of action, along with the combination selection of targets. Cambridge Healthtech Institute’s Inaugural Bispecific Antibody Design and Applications will focus on the challenges of bispecific development and their applications for immuno-oncology therapies including cytotoxic effector cell redirecting such as T-cell and NK-cell engagers, enhancing the efficacy and internalization of antibody-drug-conjugates (ADCs) and many more.

Preliminary Agenda

KEYNOTE PRESENTATION: Current Landscape and Outlook of Bispecific Antibody

Roland Kontermann, PhD, Professor, Biomedical Engineering, Institute of Cell Biology and Immunology, University of Stuttgart, Germany

T CELL ENGAGERS

Advancing T Cell-Engaging Bispecific Antibodies and Optimized Cytokines for Immuno-Oncology

Matthew J. Bernett, PhD, Associate Director, Protein & Antibody Engineering, Xencor, Inc.

Managing T Cell Activation and Macrophage Differentiation with a Dual Player Nanofitin to Treat Cancer

Mathieu Cinier, PhD, Scientific Director, Affilogic

BISPECIFIC ANTIBODY AND ANTIBODY-DRUG CONJUGATES (ADCs)

Bispecific Antibodies and Antibody-Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs

Julian Andreev, PhD, Research Fellow, Oncology & Angiogenesis, Regeneron Pharmaceuticals Inc.

ZW49 – A Novel Bispecific Antibody-Drug Conjugate (ADC) Targeting HER2-Expressing Cancers

John Babcook, PhD, Senior Vice President, Discovery Research, Zymeworks

TECHNOLOGIES FOR BISPECIFIC ANTIBODY DISCOVERY AND OPTIMIZATION

Unbiased Functional Screening of Large Bispecific Antibody Panels to Unlock Novel Biology

Mark Throsby, PhD, CSO, Merus NV

CB213: A Trispecific Dual Checkpoint Inhibitor Optimally Configured for Therapeutic Efficacy

James Legg, PhD, Senior Vice President, Research, Crescendo Biologics

Discovery, Optimization, and Developabilty Profiling of Common Light Chain CD3 Bispecifics

Paul Widboom, PhD, Associate Director, Antibody Discovery, Adimab LLC

CLINICAL UPDATES

ATOR-1015 - From Discovery to the Clinic

Anne Mansson-Kvarnhammar, PhD, Senior Scientist, Alligator Bioscience AB

Updates on Development and Applications of Roche’s Bispecific Platform

Marlon J. Hinner, PhD, Principal Scientist, Group Leader Phage Display, Large Molecule Research, Roche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Germany

Advances in Immunotherapy: Maximizing T Cell Responses with Tumor Antigen-Directed Bispecific Antibodies and Co-stimulation

Maria Karasarides, PhD, Executive Director, ImmunoOncology, Regeneron Pharmaceuticals

For more details on the conference, please contact:
Emily Le

Conference Producer

Cambridge Healthtech Institute

Phone: (+1) 781-247-1812
Email: ele@healthtech.com

For partnering and sponsorship information, please contact:

Rod Eymael

Manager, Business Development

Cambridge Healthtech Institute

Phone: (+1) 781-247-6286
Email: reymael@healthtech.com